MedPAC chair defends Medicare Advantage overpayment analysis at insurer lobby event
Amid growing public debate over how best to analyze spending in MA versus traditional Medicare, Dr. Amol Navathe, the leader of the group behind the most-cited estimate, stepped into the lion’s den to support its work.
We haven't written up this one. Healthcare Dive has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.
- Oz: Medicare Advantage a garden ‘vulnerable to weeds and overgrowth’ healthcaredive.com
